Associate Dean for Graduate Programs
University of Maryland
Andrew Coop is Professor and Associate Dean for Graduate Programs at the University of Maryland School of Pharmacy. He received the James E. Wynn Memorial Award from the Chemistry Section of the American Association of Colleges of Pharmacy in 2014, the “2019 Chemist of the Year” by the American Chemical Society - Maryland Section, the Joseph Cochin Young Investigator Award from the College on Problems of Drug Dependence in 2003, and is a Fellow of both the College on Problems of Drug Dependence and the American Association of Pharmaceutical Scientists. However, his most proud achievement is that four of his graduate student mentees are now faculty members themselves at schools of pharmacy.
He received funding from NIDA for interdisciplinary projects concerned with drugs of abuse, and described UMB425 as a novel opioid analgesic with lower tolerance and dependence than morphine, which resulted in the spin-off company, ALT Pharmaceuticals, LLC. He has published over 130 manuscripts, reviews, and patents concerned with the chemistry and pharmacology of drugs of abuse.
Dr. Coop has a passion for communication with the public on the impact of science, and particularly drugs of abuse, having been quoted in The Atlantic, The Smithsonian, the Washington Post, and the best-selling book “Dreamland”. He acts as an expert witness for the US Department of Justice in federal criminal trials, and testified to the US Senate HELP Committee in February 2019 on approaches to treat pain during the opioid crisis (Link: https://www.help.senate.gov/hearings/managing-pain-during-the-opioid-crisis )
.png)